Project Grant R41AR083760
Award Date
8/22/24
Completion Date
7/31/25
Dollars Obligated
$563K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
Federal Grant Program
93.351
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This Cooperative Agreement from the National Institutes of Health (NIH) under the 21st Century Cures Act: Regenerative Medicine Initiative (CFDA 93.370) provides $538,200.00 to The Regents of the University of Colorado, doing business as the University of Colorado-Denver, to conduct a Phase 1 pilot study on the safety and efficacy of induced pluripotent stem cell (iPSC)-based therapy for recessive dystrophic epidermolysis bullosa (RDEB). The study will evaluate the use of genetically...
This Project Grant award, made by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports the development of Dermisphere, an advanced dermal regeneration scaffold product by Fesariustherapeutics Inc. The $349,345 award aims to demonstrate the feasibility of using Dermisphere to manage acute major burn wounds. Preliminary studies have shown that Dermisphere can support rapid and sustained cellular...
This Project Grant award of $1,558,753.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the University of Cincinnati in conducting tissue engineering research for cutaneous and systemic epidermolysis bullosa gene therapy. The award period runs from September 1, 2023 to August 31, 2026. The University of Cincinnati, through its Sponsored Research Services Division, is the prime awardee on this grant. As a subcontractor, the...
The Ohio State University was awarded a $971,401 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct tissue engineering research for cutaneous and systemic epidermolysis bullosa gene therapy. The project will run from September 1, 2023 to August 31, 2026. Epidermolysis bullosa is a rare genetic condition that causes fragile, blistering skin. This research aims to develop innovative gene therapy treatments to address...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $295,294 Phase I SBIR project grant (CFDA 93.846) to Gigamune, Inc. to develop a novel lentiviral gene delivery platform for in vivo delivery of the full-length dystrophin gene to muscle cells. The goal is to create an efficient and targeted approach for gene therapy to treat Duchenne muscular dystrophy, a severe genetic disorder causing muscle wasting. The project aims to leverage Gigamune's...
The Defense Health Agency awarded a $4.66 million project grant to the University of Colorado Denver to support research on a stem cell-based therapy for recessive dystrophic epidermolysis bullosa delivered with a spray-on skin device. The grant was awarded on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420) and will run through August 31, 2027. Through this funding, the University of Colorado Denver will conduct research to develop an innovative stem...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) provides $1,031,651 to the University of California, San Diego to develop a novel therapeutic delivery system called "Cargocytes". The Cargocytes are derived from mesenchymal stem cells that have been genetically engineered and enucleated to enable precise targeting and delivery of...
This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), aims to develop a novel therapeutic approach to improve angiogenesis and wound healing by delivering apoptotic neutrophils within a degradable hydrogel scaffold. The $172,700 award, effective August 20, 2024 through July 31, 2026, supports research to investigate the effects of the hydrogel-apoptotic neutrophil delivery on macrophage angiogenic signaling and its impact...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...
This $306,872 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 is supporting Vivreon Biosciences, LLC, a life sciences company in San Diego, California, to develop a novel small molecule therapeutic targeting the ORAI1 calcium channel for treating Duchenne muscular dystrophy (DMD) and other dystrophinopathies. The key objectives of this 2-year project are to assess the toxicity profile of the therapeutic candidate and...